MF59 adjuvant-induced innate immune activation (null)

The MF59 adjuvant is an oil-in-water emulsion used in licensed influenza vaccines to enhance immune responses, mainly by stimulating the early innate immune system. Rather than acting through a single defined molecular target, MF59 rapidly induces a local pro-inflammatory environment at the site of injection, driving the recruitment of innate immune cells, including monocytes and neutrophils. These cells facilitate antigen uptake and migration to draining lymph nodes, where MF59 further promotes the differentiation of monocytes into dendritic cells. This cascade enhances antigen presentation and stimulates both cellular and humoral adaptive immune responses. MF59 functions in part by triggering the release of endogenous danger signals (e.g., ATP), but does not directly engage canonical pattern recognition receptors such as TLRs; some adjuvant effects require MyD88 and ASC adaptor proteins[1][2][3][4][5][6][7]. Thus, "innate immune activation via MF59 adjuvant" refers to a coordinated biological process rather than a single molecule or receptor.

Other names

MF59 adjuvant mechanismMF59 innate immune activationMF59 adjuvanticity

MF59 recruits innate immune cells (e.g., monocytes, neutrophils) to the injection site by inducing local chemokines and cytokines Promotes differentiation of monocytes into dendritic cells in draining lymph nodes, enhancing antigen presentation MF59 increases extracellular ATP release, which acts as a danger signal and activates immune cells[7] MF59 does not directly activate known Toll-like receptors (TLRs), and its activity is partly independent of classical PRR pathways, though requires MyD88 and ASC adaptor proteins for full adjuvant activity[2][6]